MedPath

The impact of Sulpiride (600mg; a dopamine antagonist) on behavioural and electrophysiological measures of visuospatial attention and inhibitio

Phase 1
Recruiting
Conditions
Spatial Attention Deficits
Inhibitory Control Deficits
Registration Number
ACTRN12617000652370
Lead Sponsor
Professor Mark Bellgrove
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath